Place de l'évidement axillaire et nouvel aspect technique dans le traitement chirurgical du cancer du sein.

In case of invasive breast cancer, the pathologic assessment of axillary lymph nodes status gives information on staging, prognosis and on the use of systemic adjuvant therapy. Removing at least ten axillary lymph nodes seems to prevent complications arising from uncontrolled tumor growth in the axilla. An axillary dissection is not justified in ductal carcinoma in situ (DCIS). To assess new techniques of axillary dissection will probably help to decrease the complications of the classical approach with oncological safety. Liposuction and endoscopic biopsies seem to give good results in preliminary studies.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

The sentinel node in breast cancer: acceptable false-negative rate.

Letterinfo:eu-repo/semantics/publishe

Screening for breast cancer with mammography.

CommentLetterinfo:eu-repo/semantics/publishe

Screening mammography re-evaluated.

CommentLetterinfo:eu-repo/semantics/publishe

Screening mammography in elderly women. Research on Breast Cancer in Older Women Consortium.

CommentLetterinfo:eu-repo/semantics/publishe

Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.

The results of available clinical studies suggest that breast cancer treatment significantly affect bone turnover, BMD and fracture risk. This is for instance the case for all third-generation aromatase inhibitors. For these reasons it is recommended that breast cancer patients exercise regularly and take daily calcium (1500 mg) and vitamin D (800UI) supplements. Most experts recommend that all women starting medical castration or aromatase inhibitor therapy should be assessed for their risk of osteoporosis and undergo bone mineral density (BMD) measurement by dual-energy X-ray absorptiometry (DEXA). Patients with pre-existing osteopenia and osteoporosis should be evaluated for conditions which worsen skeletal health, such as vitamin D deficiency, hyperparathyroidism, hyperthyroidism and hyper-calcuria. If these patients have a BMD score of -2.5 or lower, a low BMD (T-score between -1 and -2.5) and additional risk factors for osteoporosis or fragility fractures, bisphosphonate therapy should be considered. The optimal duration of bisphosphonate therapy is unknown. It should probably be given for as long as aromatase inhibitor therapy is continued. In addition, bisphosphonate therapy may also reduce the risk of bone metastases. This approach seems to be cost effective based on an economic evaluation model.EditorialSCOPUS: ed.jinfo:eu-repo/semantics/publishe

Effect of screening programme on mortality from breast cancer. Women might not accept mammography if benefit is lower than is currently thought.

CommentLetterinfo:eu-repo/semantics/publishe

Principal cancers among women: Breast, lung and colorectal

SCOPUS: cp.jinfo:eu-repo/semantics/publishe

Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006

Introduction: The optimal clinical management of breast cancer (BC) arising in BRCA1/2 mutations carriers is a difficult issue complicated by the risk of subsequent malignancies and by the potential differences in response to local and systemic therapies. Aim: Systematically review the difference in outcome after breast conservation therapy (BCT) and uni-or bilateral mastectomy in BRCA1/2 related BC. Material and methods: We selected 20 studies, for which we evaluated the methodology, the characteristics of the populations, biases, confounding risk factors and outcomes. Results: All studies are retrospective, entailed by numerous biases. They varied with respect to patients' number, selection, and confounding factors. Hereditary BC patients carried an increased risk of ipsilateral recurrence in 5/17 studies, a worse survival in 4/14, an increased risk of contralateral BC in 14/16. Conclusion: Except for contralateral risk, the presence of a BRCA mutation does not seem to offer additional prognostic information. Large prospective trials, stratified for risk reduction strategies are warranted. © 2006 Elsevier Ltd. All rights reserved.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Compliance to hormone replacement therapy.

SCOPUS: re.jinfo:eu-repo/semantics/publishe